T1	Participants 51 72	mild asthma patients:
T2	Participants 285 306	mite-allergic asthma.
T3	Participants 495 536	mite monosensitive, mild asthma patients.
T4	Participants 603 678	26 asthma patients who randomly received vaccination or placebo for 1 year.
T5	Participants 2074 2094	mild asthma patients
